Mark Charles Sultzman, PA-C, PharmD

Mark Sultzman practices at Vero Orthopaedics II PA in Sebastian, Florida.

Mark Sultzman's NPI, 1841524527, was assigned on September 28, 2009. Mark Sultzman holds Florida license PAT9105191.

Mark Sultzman's primary practice is Vero Orthopaedics II PA, at 801 Wellness Way, Sebastian, FL 32958 in Indian River County. The practice phone is (772) 569-2330.

Mark Sultzman's primary practice is Vero Orthopaedics II PA in Sebastian, Florida. Mark Sultzman is also affiliated with Orlando Health Sebastian River Hospital. The medical group on file is Vero Orthopaedics. Dmand AI also links Mark Sultzman to 1 more hospital, 2 group practices and clinics, 1 home health agency and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Mark Sultzman practices, 5 sites in all. Vendor and product names are available with a free account.

Medical is Mark Sultzman's primary specialty in the NPI Registry, under taxonomy code 363AM0700X. Mark Sultzman is board certified in certified physician assistant by the National Commission on Certification of Physician Assistants (NCCPA). Mark Sultzman is licensed in Florida.

Dmand AI lists acute gastroduodenitis, acute mini-stroke (TIA), acute sinusitis, acute skin infection, adjustment disease, alzheimer's disease, ankle or foot injury and anxiety among the conditions Mark Sultzman treats.

CMS data shows 4,121 Medicare services from Mark Sultzman across 19 procedure codes in 2024, for 736 Medicare patients. Medicare paid $173,224 for them. Every service was in an office.

CMS counts 736 Medicare patients who saw Mark Sultzman in 2024. The largest group is 65 to 74, with 389 patients. 75% of them have high cholesterol, and 73% have arthritis. 2% are also on Medicaid. Their average risk score is 0.95, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Mark Sultzman's median patient age at 69, with 50% women.

In 2024, Mark Sultzman wrote 5,529 Medicare Part D claims for 478 patients. 85% of them were for generic drugs. CMS names the drug for 4,830 of them, across 98 drugs with 11 or more claims each, at $493,312 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Mark Sultzman for performance year 2024, reported as part of a group. Mark Sultzman accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Mark Sultzman as offering telehealth.

CMS Open Payments shows 24 general payments to Mark Sultzman from 11 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 82% of the total. Medical Device Business Services, Inc. paid the most, $98.